Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768242 | 0.99 | SLC6A2 (0.47) | SLC6A2SLC6A4HTR6DRD2DRD3 | |
| SCHEMBL2767419 | 0.88 | SLC6A2 (0.46) | SLC6A2SLC6A4HTR6DRD2DRD3 | |
| SCHEMBL2766672 | 0.84 | SIGMAR1 (0.59) | HTR6SIGMAR1 | |
| SCHEMBL2769523 | 0.82 | HTR6 (0.50) | HTR6SIGMAR1TMEM97 | |
| SCHEMBL2766225 | 0.81 | HTR6 (0.49) | HTR6SIGMAR1TMEM97 | |
| SCHEMBL2478773 | 0.78 | HTR6 (0.67) | SLC6A4HTR6SIGMAR1TMEM97 | |
| SCHEMBL2766690 | 0.77 | DRD2 (0.42) | SLC6A2SLC6A4DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2766446 | 0.76 | DRD2 (0.41) | SLC6A2SLC6A4DRD2DRD3 | |
| SCHEMBL2768765 | 0.76 | CHRM4 (0.47) | DRD2DRD3CTSLCTSSCTSK | |
| SCHEMBL2767785 | 0.76 | SIGMAR1 (0.56) | HTR6DRD2DRD3SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | SLC6A2 1829/4885SLC6A4 1148/4885HTR6 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.